Global secretome characterization of A549 human alveolar epithelial carcinoma cells during Mycoplasma pneumoniae infection by Shuxian Li et al.
Li et al. BMC Microbiology 2014, 14:27
http://www.biomedcentral.com/1471-2180/14/27RESEARCH ARTICLE Open AccessGlobal secretome characterization of A549 human
alveolar epithelial carcinoma cells during
Mycoplasma pneumoniae infection
Shuxian Li1, Xuejing Li1, Yingshuo Wang1, Jun Yang3*, Zhimin Chen1* and Shigang Shan2,3Abstract
Background: Mycoplasma pneumoniae (M. pneumoniae) is one of the major etiological agents for community-acquired
pneumonia (CAP) in all age groups. The early host response to M. pneumoniae infection relies on the concerted release
of proteins with various biological activities. However, no comprehensive analysis of the secretory proteins has been
conducted to date regarding the host response upon M. pneumoniae infection.
Results: We employed the liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based label-free quantitative
proteomic technology to identify and characterize the members of the human alveolar epithelial carcinoma A549 cell
secretome during M. pneumoniae infection. A total of 256 proteins were identified, with 113 being differentially expressed
(>1.5-fold change), among which 9 were only expressed in control cells, 10 only in M. pneumoniae-treated cells, while 55
were up-regulated and 39 down-regulated by M. pneumoniae. The changed expression of some of the identified proteins
was validated by RT-PCR and immunoblot analysis. Cellular localization analysis of the secretome data revealed 59.38% of
the proteins were considered as “putative secretory proteins”. Functional analysis revealed that the proteins affected upon
M. pneumoniae infection were mainly related to metabolic process, stress response, and immune response. We further
examined the level of one up-regulated protein, IL-33, in clinical samples. The result showed that IL-33 levels were
significantly higher in the plasma and bronchoalveolar lavage fluid (BALF) of M. pneumoniae pneumonia (MPP) patients.
Conclusions: The present study provided systematic information about the changes in the expression of secretory
proteins during M. pneumoniae infection, which is useful for the discovery of specific biomarkers and targets for
pharmacological intervention.
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Mycoplasma pnuemoniae (M. pneumoniae) belongs to
the class of the Mollicutes and is one of the smallest
free-living organisms. It is a major cause of community-
acquired pneumonia (CAP) worldwide in all age groups,
and can also induce manifestations in extrapulmonary
sites involving almost all organs of the human body [1,2].
With the exception of M. pneumoniae adherence to the
host epithelium, molecular mechanisms underlying the
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unless otherwise stated.mystery [1]. Subsequent to cytadherence, M. pneumoniae
is believed to cause disease in part through the generation
of peroxide [3] and the induction of inflammatory reaction
including cytokine productions (e.g. IL-8, TNF-α, and
IL-1β) [4]. Simultaneously, autoimmunity developed after
M. pneumoniae infection likely contributes to the extrapul-
monary complications. For example, anti-GM1 and galac-
tocerebroside antibodies are the primary autoantibodies
implicated in the ascending paralysis of Guillain-Barre syn-
drome and in encephalitis associated with M. pneumoniae
[5,6]. Although toxin had not been considered as part of
the M. pneumoniae repertoire in previous studies, recent
evidence suggested otherwise. A newly identified exotoxin
ofM. pneumoniae, named community-acquired respiratory
distress syndrome toxin (CARDS TX), which has ADP-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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to be responsible for eliciting extensive vacuolization
and ciliostasis of host cells [7]. Thus, the pathophysiology
of M. pneumoniae infection is likely to be complex and
multifactorial, and the underlying molecular mechanisms
should involve a large number of genes/proteins participat-
ing in various biological pathways [3,8,9]. High-throughput
technologies including genomics and proteomics can com-
prehensively and quantitatively decipher gene/protein ex-
pression, and therefore, are useful tools in the study of
complex systems under the influence of biological pertur-
bations, such as pathogen-host interaction [10]. Previously,
using a proteomic approach, we had analyzed M. pneumo-
niae-induced protein expression profile using whole cell ly-
sates, and identified the redox regulatory pathway as a key
target during M. pneumoniae infection [3]. However, as
noted above, M. pneumoniae-induced immune response is
important for M. pneumoniae pathogenesis, and many fac-
tors involved in the immune response, such as the cyto-
kines, are so-called secretory proteins, which are part of
the “secretome” [11].
Secretome proteins include extracellular matrix pro-
teins, growth factors, cytokines and hormones, and other
soluble mediators. It is known that secretory proteins
are important for many physiological processes [11,12].
For example, the matrix metalloproteinases (MMPs), as
extracellular matrix-degrading enzymes, are essential regu-
lators of the cell’s microenvironment governing cell fate
and function, such as cell migration, proliferation, apop-
tosis, invasion and development [13]. Moreover, changes in
secretory proteins can reflect different conditions of the
cells or tissues. For instance, Lietzen et al. revealed dra-
matic changes in secretome of macrophages, such as robust
secretion of different danger-associated molecular patterns
(DAMP), in response to influenza A infection [10]. Arturo
et al. found that muscle secretion pattern varied accord-
ing to fiber-type constituents (e.g. slow-oxidative com-
pared to fast-glycolytic muscle), and the secretome could
be affected by endurance exercise training [14]. Conse-
quently, secretome represent an important source for bio-
marker and therapeutic target discovery [12]. For that
importance, secretomics, a branch of proteomics, focusing
on analyzing the profile of all proteins secreted from cells
or tissues, has been developed in recent years [15].
In addition, recent studies have showed that secretory
proteins are also important for certain disease condi-
tions. For example, dysregulation of adipocytokines (e.g.
TNF-α, plasminogen activator inhibitor type 1 (SER-
PINE1), heparin-binding epidermal growth factor-like
growth factor) and adiponectin contributes to the develop-
ment of a variety of cardiovascular disease [16]. Similarly,
secretory proteins also play a role in infectious disease. For
instance, changes in the expression of secretory proteins
during latent human cytomegalovirus (HCMV) infectionhave profound effects on the regulation of the host im-
mune response, such as recruitment of CD4+ T cells by
increasing the expression of CC chemokine ligand 8
(CCL-8) [17]. Also, the secreted IFN-induced proteins
(e.g. interferon-induced tetratricopeptide proteins 2 (IFIT2),
IFIT3, signal transducer and activator of transcription 1
(STAT1)) were indicated to have important extracellular
antiviral functions during Herpes simplex virus 1 (HSV-1)
infection [18]. Together, these data indicate the import-
ant role of secretory proteins in host-pathogen inter-
action. However, although M. pneumoniae infection is a
common cause of respiratory disease, secretome change
during M. pneumoniae infection had not been thoroughly
investigated.
Airway epithelial cells form the first line of defense
against exposure to infectious agents. Epithelial cells are
known to kill or neutralize microorganisms through the
production of enzymes, permeabilizing peptides, collec-
tins, and protease inhibitors during the innate immune
response [19]. Epithelial cells are also essential in regu-
lating adaptive immune responses in the airways by ex-
pressing pattern-recognition receptors (PRRs) to trigger
host defense response, by activating dendritic cells to
regulate Ag sensitization, and by releasing cytokines to
recruit effector cells [4,19,20]. Thus, airway epithelial cells
are important for the initiation, maintenance, and regula-
tion of both innate and adaptive immune responses, as
well as modulating the transition from innate to adaptive
immunity. As the interaction of M. pneumoniae with re-
spiratory epithelial cells is a critical early step of pathogen-
esis [21], and considering the importance of secretory
proteins, a large-scale study on M. pneumoniae-induced
protein secretion will help elucidate the molecular mecha-
nisms related to M. pneumoniae infection.
Therefore, in the current study, we applied liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
based label-free quantitative shotgun proteomics approach
for global profiling of the M. pneumoniae-infected human
alveolar epithelial carcinoma A549 cell secretome, in an
effort to provide a better view of host-pathogen inter-
action and identify novel molecules/biomarkers for M.
pneumoniae infection. As reported here, we have identi-
fied 113 proteins affected by M. pneumoniae infection.
Furthermore, we evaluated the clinical application of one
identified protein, IL-33, as a “proof of concept” example,
and the result showed that it could help to distinguish
M. pneumoniae pneumonia (MPP) patients from non-
M. pneumoniae patients.
Results
Label-free quantitative shotgun proteomic analysis of cell
secretome upon M. pneumoniae infection
The study design is outlined in Figure 1. Both cell viabil-
ity and apoptosis assay revealed that serum free medium
Figure 1 Workflow chart of the experimental design.
Figure 2 Verification of up- or down-regulated proteins during
M. pneumoniae infection. (A) RT-PCR analysis and quantitative
analysis data of 16 secertory proteins during M. pneumoniae infection.
compared to control (p < 0.05); data are presented as means ± SD.
(B) Western blot analysis for 6 secretory proteins from total cell lysates
and culture supernatants. Representative images were from three
independent experiments performed in duplicate. β-actin was used as
internal control for total cell lysates.
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tion capacity within 24 h (see Additional files 1 and 2:
Figures S1 and S2), and thus serum-free culture for 24 h
was chosen as the time point for secretome collection.
Based on the LC-MS/MS data, 233 proteins were iden-
tified in control A549 cells, with 187 being identified
from all three biological replicates (see Additional file 3:
Figure S3A), indicating a relatively good reproducibility.
Similarly, 237 proteins were identified in M. pneumoniae-
infected A549 cells, with 199 being identified from all three
biological replicates (see Additional file 3: Figure S3B).
Thus, a total of 256 proteins were identified, among which
214 proteins were detected in both groups, with 19 and 23
proteins being uniquely secreted by control cells and
M. pneumoniae-infected cells, respectively (see Additional
file 3: Figure S3C). Complete protein identification lists for
control and M. pneumoniae-infected cells were provided
in Additional files 4 and 5: Datasheet S1 and Table S1.
For the identified proteins, label-free quantitative com-
parison performed by DeCyder™ MS Differential software
revealed that 113 proteins were significantly affected by M.
pneumoniae infection (fold difference ≥1.5 or ≤0.67) (see
Additional file 6: Table S2). Specifically, there were 65 up-
regulated and 48 down-regulated proteins in M. pneumo-
niae-infected A549 cells, among which 10 were uniquely
expressed in M. pneumoniae-treated A549 and 9 in con-
trol A549 cells. For all 113 differential proteins, the num-
ber of peptides for each protein used for quantification
varied from 1 to 13. Among them, 33 proteins were quan-
tified on the basis of two or more peptides, with average
coefficient of variation (CV) of the fold changes for
peptides as 16.80% (range from 0.00% to 39.21%, see
Additional file 6: Table S2), demonstrating a rational re-
producibility of the quantitative data. The rest 80 proteins
were quantified with only one peptide by the DeCyder
software.Validation of proteins with changed expression during
M. pneumoniae infection
To verify the proteomic results, real-time PCR and
Western blot analysis were performed on several identi-
fied proteins. The real-time PCR results demonstrated
that the gene expression levels of 16 secretory proteins
exhibited the same trend of changes as the quantitative
MS results (Figure 2A). Also, Western blot data showed
that protein levels of six secretory proteins were signifi-
cantly increased in the CM and total cell lysates after
M. pneumoniae-infection, which were consistent with
the proteomic results (Figure 2B). Therefore, from the
RT-PCR and Western blot results, we found that these
six secretory proteins (ADAM9, SERPINE1, IL-33, IGFBP4,
Gal-1, MIF) were overexpressed inM. pneumoniae-infected
A549 cells at mRNA and protein levels.Cellular localization of the identified proteins
The 256 identified proteins were first categorized as clas-
sical secretory proteins or non-classical secretory proteins
based on SingalP and SecretomeP analysis. Of the 256
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and 69 as non-classical secretory proteins (see Additional
file 5: Table S1). To determine whether some of the pro-
teins could also be released via exosomes, the Exocarta
exosome database were searched [22]. The results showed
that among the proteins identified, 190 proteins were
also listed in the exosomal protein database (see Additional
file 5: Table S1).
We next analyzed the ontology of the identified pro-
teins based on cellular compartment. The results showed
majority of the proteins belong to more than one GO class
(Figure 3). Most of the proteins have a nuclear distribution
(Figure 3A). Functional annotation clustering analysis byFigure 3 Cellular localization of identified proteins. (A)
Distribution of the identified proteins based on gene ontology (GO)
annotations. (B) Enrichment score of GO cellular component
categories. DAVID 6.7 was used to analyze the GO classification of
the identified proteins. Function annotation clustering was used to
classify similar annotation terms together, and the enrichment score
for each group was used to rank the overall over-representation of
annotation terms. The higher the enrichment score, the more
important were the members of the annotation cluster.DAVID 6.7 showed that when considering only cellular
compartment distribution, the proteins of the extracel-
lular region, vesicle and extracellular matrix were over-
represented (enrichment score (ES) of 12.24, 8.57, and
3.98, respectively) (Figure 3B). Similarly, the classifica-
tion based on the cellular organelle of the differentially
expressed proteins also showed that M. pneumoniae infec-
tion did not induce protein secretion from any specific cell
organelle, but rather, altered the overall secretion of pro-
teins from all the main organelles, including mitochon-
drion and lysosome (Figure 4 and see Additional file 7:
Figure S4A). Enrichment in proteins residing in the extra-
cellular region, especially extracellular matrix, extracel-
lular space, and membrane-bound vesicle was observed
(Figure 4 and see Additional file 7: Figure S4A). More-
over, when p value < 0.05 was set as the threshold, 46
GO terms for up-regulated proteins and 10 for down-
regulated proteins were obtained, respectively (Figure 4
and see Additional file 7: Figure S4A).Functional classification of the differentially expressed
secretory proteins
To better understand the nature of the differentially ex-
pressed proteins, the KEGG database was used for pathway
analysis, which evaluates the relative importance of the
change in a pathway/function in response to treatment
and/or change in physiological state. Eleven pathways were
listed in the KEGG database (p < 0.1) after M. pneumoniae
infection, of which 8 were significantly over-represented
(p < 0.05) (Table 1). The significantly over-represented
KEGG pathways were related to metabolism, infection,
and proliferation (Table 1).
In addition, an enrichment analysis was performed by
BiNGO for the differentially expressed proteins. For the
up-regulated proteins, GO analysis revealed 19 molecular
function GO categories associated with oxidoreductase ac-
tivity, 18 related to protein binding, and 16 linked to en-
zyme regulator activity (see Additional file 7: Figure S4B),
while for the down-regulated proteins, 54 GO terms were
identified, which were mainly associated with enzyme in-
hibitor activity and hydrolase activity (see Additional file 7:
Figure S4C).
Biological processes analysis of up-regulated proteins
led to the identification of functional groups related to
monosaccharide catabolic process, inflammatory response,
cell redox homeostasis, and defense response (see
Additional file 7: Figure S4D). For the down-regulated
proteins, system development seemed to be the most rele-
vant biological process (see Additional file 7: Figure S4E).
Based on the BiNGO biological process analysis, we iden-
tified 17 up-regulated proteins that were involved in im-
mune response, and 36 up-regulated proteins might act as
endogenous danger signals [23,24] (Table 2).
Figure 4 Functional gene ontology (GO) analysis of cellular compartment distribution of the clusters of proteins that were up-regulated by
M. pneumoniae treatment. Over-representation of GO categories was analyzed using the Biological Networks Gene Ontology plugin (BINGO, version
2.44). Over-representation statistics were calculated by using the hypergeometric analysis and Benjamini & Hochberg False Discovery Rate (FDR) correction.
Only categories that are significantly enriched after correction are represented. The color scales indicate the p value range for over-representation. The node
size is proportional to the number of proteins annotated with the GO term.
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M. pneumoniae infection
As mentioned earlier, pathogen-host interaction is a very
complex process and many proteins are involved. Also, bio-
logical association network changes in protein expression
are not isolated events [25]. Therefore, in this study, we
want to know how differentially expressed proteins inter-
act with each other and how they affect cell’s function dur-
ing M. pneumoniae infection. The biological associationsamong the differentially expressed proteins were investi-
gated using the STRING software. The predicted protein-
protein associations were queried through a vast number
of databases derived in different ways (e.g. experimentally
determined interactions, protein neighborhood data, or
data acquired via text mining) [26]. As shown in Figure 5,
for the 65 up-regulated proteins, three main networks of
protein interactions were identified, including stress re-
sponse proteins (red circle), signaling pathway associated
Table 1 KEGG analysis of differential expressed protein after Mycoplasma pneumoniae infection
Category Term Count % p value Genes
KEGG_PATHWAY hsa00620:Pyruvate metabolism 6 5.31 1.46E-04 3939, 4191, 4190, 231, 5315, 3945
KEGG_PATHWAY hsa00010:Glycolysis/Gluconeogenesis 6 5.31 9.95E-04 3939, 7167, 2023, 5315, 3945, 2821
KEGG_PATHWAY hsa04114:Oocyte meiosis 7 6.19 2.83E-03 10971, 7529, 5501, 801, 7534, 7532, 7531
KEGG_PATHWAY hsa00030:Pentose phosphate pathway 4 3.54 3.92E-03 2539, 7086, 2821, 5226
KEGG_PATHWAY hsa00270:Cysteine and methionine metabolism 4 3.54 9.38E-03 3939, 191, 3945, 2805
KEGG_PATHWAY hsa04722:Neurotrophin signaling pathway 6 5.31 2.17E-02 10971, 7529, 801, 7534, 7532, 7531
KEGG_PATHWAY hsa00480:Glutathione metabolism 4 3.54 2.65E-02 2950, 2539, 2936, 5226
KEGG_PATHWAY hsa05130:Pathogenic Escherichia coli infection 4 3.54 3.72E-02 10971, 7534, 3875, 10376
KEGG_PATHWAY hsa04810:Regulation of actin cytoskeleton 7 6.19 5.89E-02 80310, 4478, 5501, 2335, 81, 5216, 1072
KEGG_PATHWAY hsa00051:Fructose and mannose metabolism 3 2.65 7.14E-02 7167, 231, 57016
KEGG_PATHWAY hsa04110:Cell cycle 5 4.42 7.82E-02 10971, 7529, 7534, 7532, 7531
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(green circle). For the 48 down-regulated proteins, two
major networks of the associated proteins were found, in-
cluding the glucose catabolic proteins (black circle) and
biological process negative regulation associated proteins
(purple circle) (Figure 6).
Clinical examination of IL-33 expression in plasma
and BALF
To explore the potential clinical application of secretomic
data, we selected one of the identified proteins, IL-33, and
examined its expression in the plasma and BALF of MPP
patients, using age-matched patients with foreign body
as comparison cohort. Patient information was listed in
Table 3. First it was shown that IL-33 secretion was induced
in A549 cells by M. pneumoniae infection (Figure 7A). Re-
sults from the measurements of patient samples also
showed that IL-33 level was significantly higher in both
plasma and BALF of MPP patients than those in patient
with foreign body (Figure 7B and 7C). To further evaluate
whether the increased plasma IL-33 levels had any potential
clinical significance as a possible biomarker for helping dis-
tinguish MPP patients from controls, a receiver operating
characteristic (ROC) curve was constructed by plotting
sensitivity vs. specificity. The area under the ROC curve
(AUC), a commonly used indicator for estimating the
diagnostic efficacy of a potential biomarker, was subse-
quently calculated. For differentiating MPP patients from
controls, the AUC was determined to be 0.727 (95% confi-
dence interval, 0.580-0.873) for plasma IL-33 (Figure 7D).
When a cutoff value of 129.08 pg/ml was set for plasma IL-
33, the sensitivity and specificity for discriminating MPP
patients from controls were 70.0% and 73.3%, respectively.
Discussion
By using comprehensive MS-based proteomics combined
with label-free quantitation algorithms, we examined the
secretome of M. pneumoniae-infected and uninfected A549cells. This proteomic approach allows the simultaneous
observation of alternation in protein expression, which may
represent a forecast to disease development or a conse-
quence of the disease [27]. As reported here, a total of 256
proteins were identified, among which 113 were differen-
tially secreted by M. pneumoniae-infected A549 cells versus
control. This result is similar to a study conducted by
Brioschi et al., in which 273 proteins were identified and
112 differentially expressed in the endothelial cell secre-
tome upon reductase inhibitor treatment [28].
Among the identified proteins, 152 proteins were des-
ignated as putative secretory proteins by using SignalP
and SecretomeP. Interestingly, 69 out of the 152 proteins
were categorized as non-classical secretory proteins, sug-
gesting that the unconventional protein release is also a
major mechanism. More importantly, as exosomal re-
lease is also regarded as a non-classical secretion mech-
anism [29], it was shown that 74% (190 out of 256) of
the identified proteins in our study can be found in the
ExoCarta database, highlighting a critical role for exo-
some in cell-cell communication [22]. In summary, up
to 92% (236 out of 256) of the identified proteins could
be transported to the extracellular space by at least one
of the above mechanisms. Since no significant apoptosis
or necrosis was observed in our study (see Additional
file 2: Figure S2), those proteins, which were not classi-
fied as secretory proteins using the computational approach
(SignalP and SecretomeP), should be released mainly by
intracellular secretion (e.g. exosome) rather than cell lysis
[30]. Furthermore, among the 113 differentially expressed
proteins, about 80% (91) were found in the ExoCarta data-
base, suggesting that exosomal protein release might be a
major mechanism by which M. pneumoniae-infected cells
communicate with other cells. Similarly, exosome-mediated
release of proteins in influenza A virus-infected human
macrophages has also been reported, underlining the im-
portance of the exosome-mediated non-classical pathway in
cell-to-cell communication during microbial infection [10].
Table 2 Immune response and stress related proteins that were up-regulated by Mycoplasma pneumoniae infection
GO-ID Description Genes in test set
Stress related proteins and functions
9611 Response to wounding B4GALT1|YWHAZ|PROCR|LGALS1|CLU|SERPINE1|NP|IGFBP4|FN1|MIF
6950 Response to stress B4GALT1|YWHAZ|LGALS1|CLU|CST3|PRDX1|NP|TPM4|MIF|PFN1|LGALS3BP|PROCR|
AKR1B1|SERPINE1|HSPB1|CTSD|IGFBP4|FN1|ADAM9
50896 Response to stimulus LDHA|YWHAZ|CLU|PRDX1|NP|TPM4|B2M|MIF|PFN1|APP|LGALS3BP|GOT1|PROCR|
TGFBI|SERPINE1|ADAM9|ENO1|FN1|B4GALT1|LGALS1|CST3|GPI|NPC2|AKR1B1|
CFL1|CTSD|HSPB1|IGFBP4|CALM1
9615 Response to virus NPC2|CLU|CFL1|HSPB1|ENO1
55114 Oxidation reduction ALDH1A1|LDHB|LDHA|AKR1B10|AKR1B1|TXN|PGD|PRDX4|TXNRD1|PRDX1
51707 Response to other organism NPC2|CLU|CFL1|SERPINE1|HSPB1|ENO1|B2M
6979 Response to oxidative stress CLU|SERPINE1|PRDX1|TPM4|ADAM9
42221 Response to chemical stimulus YWHAZ|LGALS1|CLU|PRDX1|NP|TPM4|B2M|MIF|PFN1|GOT1|SERPINE1|CFL1|
HSPB1|CALM1|ADAM9
9607 Response to biotic stimulus NPC2|CLU|CFL1|SERPINE1|HSPB1|ENO1|B2M
10035 Response to inorganic substance SERPINE1|PRDX1|CALM1|ADAM9|B2M
10033 Response to organic substance PFN1|GOT1|LGALS1|CLU|CFL1|SERPINE1|HSPB1|MIF|ADAM9|B2M
42493 Response to drug YWHAZ|LGALS1|NP|MIF|B2M
302 Response to reactive oxygen species SERPINE1|PRDX1|ADAM9
Immune response related proteins and functions
6952 Defense response B4GALT1|PFN1|LGALS3BP|YWHAZ|CLU|SERPINE1|CST3|PRDX1|IGFBP4|FN1|MIF
6954 Inflammatory response B4GALT1|YWHAZ|CLU|IGFBP4|FN1|MIF
50900 Leukocyte migration B4GALT1|MSN|MIF
2376 Immune system process B4GALT1|GPI|YWHAZ|PROCR|CLU|MSN|NP|PRDX1|MIF|ADAM9|B2M
2441 Histamine secretion involved in inflammatory response YWHAZ
2477 Antigen processing and presentation of exogenous
peptide antigen via MHC class Ib
B2M
2481 Antigen processing and presentation of exogenous
protein antigen via MHC class Ib, TAP-dependent
B2M
2349 Histamine production involved in inflammatory response YWHAZ
35491 Positive regulation of leukotriene production involved
in inflammatory response
SERPINE1
35490 Regulation of leukotriene production involved in
inflammatory response
SERPINE1
34241 Positive regulation of macrophage fusion ADAM9
6955 Immune response GPI|YWHAZ|PROCR|CLU|NP|PRDX1|MIF|B2M
2443 Leukocyte mediated immunity YWHAZ|CLU|PRDX1
2684 Positive regulation of immune system process CLU|SERPINE1|NP|MIF|B2M
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ters of proteins were identified (Figure 5 and 6), suggesting
that these proteins often act in cooperation with each
other rather than alone during M. pneumoniae infection.
Furthermore, the functions of those differential expressed
proteins were found to be mainly associated with bio-
logical processes including immune response, metabolic
process, and stress response (see Additional file 7: Figure
S4D and S4E). Indeed, a number of studies have highlighted
the importance of host-dependent inflammatory response toM. pneumoniae infection, such as IL-12 and IFN-γ pro-
duction, as well as the Th1 type T-cell responses in a
mouse model [4,31-34]. Previously we have also shown
that the reactive oxygen species (ROS) induced by M.
pneumoniae infection attributed in part to the cytopathol-
ogy of the respiratory epithelium [3], and M. pneumoniae
infection could influence host’s sphingolipid metabolism,
including the generation of new ceramide and sphingo-
myelin species [35]. These reports, together with many
other reports, supported the finding from this secretomic
Figure 5 Protein interaction network analysis of the up-regulated proteins in M. pneumoniae-treated A549 cells. Using protein interaction
network analysis tool (STRING database), three networks of the associated proteins were found among the up-regulated proteins. These included the
network for stress response proteins (red circle), signaling pathway associated proteins (blue circle), and cellular metabolic proteins (green circle).
Different line colors represent the types of evidence for the association.
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the biological process of the host, which may partially ex-
plain the wide clinical manifestation of M. pneumoniae in-
fection [2].
Cells under stress are known to actively secrete or pas-
sively release endogenous danger signal molecules, which
include proteins and other endogenous molecules, such as
ATP and uric acid [23,36]. Interestingly, we have found 36
out of the 113 differentially expressed proteins were asso-
ciated with stress and may act as endogenous danger
signals (Table 2) [23,24], including heat shock protein
beta-1 (HSPB1), galectin-1 (Gal-1), galectin-3-binding
protein (LGALS3BP), SERPINE1, disintegrin and me-
talloproteinase domain-containing protein 9 (ADAM9),
peroxiredoxin-4 (PRDX4), and PRDX1. Several of these
danger signal proteins, such as HSPs, galectins, and redox-
related members, were also secreted during influenza A
virus or HSV-1 infection of human macrophages [10,18].
Therefore, the secretion of such danger signal proteins
might be a general host response to pathogen infection.
Some of these danger signal molecules were involved in
regulating the cellular oxidative status, such as ADAM9,Gal-1 and SERPINE1 [37-39]. In line with such observation,
M. pneumoniae is known to induce ROS production and
reduce glutathione levels in lung and lung carcinoma cells
[3,40]. Furthermore, M. pneumoniae can inhibit host cell
catalase, which could result in the toxicity of hydrogen per-
oxide in skin fibroblast and ciliated epithelial cells [41]. To-
gether, these results implicate that the enhanced ROS
production should be recognized as an important mechan-
ism in the pathogenesis of M. pneumoniae infection [3].
In addition, many identified proteins were involved in
extracellular matrix formation (Figure 4 and see Additional
file 7: Figure S4A). Extracellular matrix plays an important
role in regulating many cellular functions like adhesion,
cell shape, migration, proliferation, polarity, differentiation,
and apoptosis [42]. For example, SERPINE1, as a multifa-
ceted proteolytic factor, not only functions as an inhibitor
of the serine protease, but also plays an important role in
signal transduction, cell adhesion, and migration [43].
Similarly, ADAM9, a member of the ADAM family, is in-
volved in the proteolytic processing of multiple trans-
membrane proteins, as well as cell adhesion, migration,
and signal transduction [44]. Gal-1 also displays diverse
Figure 6 Protein interaction network generated with STRING software for down-regulated proteins in M. pneumoniae-treated A549 cells.
Two major networks, e.g., glucose catabolic proteins (black circle) and biological process negative regulation associated proteins (purple circle) were
found. Different line colors represent the types of evidence for the association.
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ment, mRNA splicing, angiogenesis and tissue differen-
tial/homeostasis, and inflammation [45]. Thus, targeting
the interplay between host cells and microenviroment
might be another important mechanism for M. pneumo-
niae pathogenesis.
Finally, we were interested in the potential clinical ap-
plication of such secretomic study, e.g. biomarker or
therapeutic target discovery [15]. To do that, we chose
one of the identified proteins, IL-33, and conducted a
“proof-of-concept” experiment. IL-33, a crucial amplifierof the innate immunity in infectious diseases as well as
in autoimmune processes, is also a recently identified
DAMP [46-48]. It has been shown that IL-33 plays an
important role in driving antiviral CD8+ T cell responses
in lymphocytic choriomeningitis virus-infected mice [47].
During the experimental intestinal nematodes (Trichuris
muris) infection in mice, IL-33 was markedly elevated
soon after infection [49]. Schmitz and co-workers demon-
strated that injection of IL-33 into mice induced a pro-
found eosinophilia with associated pathologic changes
[50], and had potent effects on eosinophil, including the
Table 3 Clinical information of patients with MPP or FB
Characteristics FB (n = 15) MPP
(n = 30)
p value
Age (years) 4.88 ± 3.58 5.78 ± 2.46 0.326
Gender (male/female) 9/6 16/14 0.671
Peripheral leukocyte (×109 cells/L) 7.00 ± 1.64 9.06 ± 4.10 0.102
Peripheral neutrophil (%) 46.95 ± 20.89 63.90 ± 16.20 0.004
BAL macrophage (%) 84.73 ± 6.45 66.53 ± 13.71 < 0.001
BAL lymphocyte (%) 9.73 ± 3.88 11.93 ± 6.39 0.229
BAL neutrophil (%) 5.53 ± 3.68 20.73 ± 13.47 < 0.001
BAL eosinophil (%) 0.20 ± 0.41 0.83 ± 2.35 0.309
Data were expressed as mean ± SD. These variables were compared using
Student’s t-test or Mann–Whitney U test.
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granulation and eosinophil survival [51]. We found M.
pneumoniae significantly increased IL-33 production in
A549 cells, and IL-33 levels were significantly higher in
MPP patients, implying an important role for IL-33 in M.
pneumoniae-elicited immune response (Figure 7). Further
ROC analysis revealed that IL-33 could help distinguish
MPP patients from patients with foreign objects. Thus,
manipulation of IL-33 might represent a promising new
therapeutic strategy for treating the inflammatory disorder
during M. pneumoniae infection.Figure 7 M. pneumoniae infection induces IL-33 expression. (A) A549
in the supernatants were measured by ELISA. Data are presented as means ±
with untreated A549 cells. (B) Concentration of IL-33 in patient plasma sampl
samples. Samples were obtained from patients with foreign body (FB, control
are presented as mean ± SD, significance was determined by Mann–Whitney
of the diagnostic efficacy of IL-33 between MPP patients and control (AUC =Conclusions
In the current study, we identified many differentially ex-
pressed secretory proteins during M. pneumoniae infection
using the quantitative label-free MS method, through which
complex regulatory networks have been revealed. Some of
the proteins could be used as lead candidates for further
functional and preclinical evaluation for their roles in M.
pneumoniae infection. Such information will shed new light
into the study of host response during M. pneumoniae in-
fection for better understanding the underlying molecular
mechanisms.Methods
Mycoplasma pneumoniae culture
M. pneumoniae strain 29342 (American Type Culture
Collection, Rockville, MD) was cultured in mycoplasma
broth at 37°C under 5% (v/v) humidified CO2, consisting
of mycoplasma broth base CM403 (OXIOD, Hampshire,
United Kingdom), mycoplasma selective supplement G
SR59 (OXIOD), 0.5% glucose, and 0.002% phenol red. Agar
plates used for colony counting were prepared similarly,
but containing mycoplasma agar base CM401 (OXIOD)
instead of mycoplasma broth base CM403. The concentra-
tion ofM. pneumoniae was quantified by measuring colony
forming units (CFU).cells were treated with M. pneumoniae for 12 and 24 h, and IL-33 levels
SD from at least three independent experiments. **, p < 0.01, compared
es. (C) Concentration of IL-33 in bronchoalveolar lavage fluid (BALF)
, n = 15) and patients with M. pneumoniae pneumonia (MPP, n = 30). Data
U test. *, p < 0.05; **, p < 0.01, compared with FB. (D) ROC curve analysis
0.727).
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As human alveolar epithelial carcinoma A549 cells (CCL-
185, ATCC) are very tolerant to SFM, we chose them as a
cell model for our secretome study [15]. Firstly, A549 cells
were maintained in phenol red-free Dulbecco’s Modified
Eagle Medium Nutrient Mixture (DMEM/F12) (Gibco,
Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS) (Gibco) at 37°C in a humidified atmosphere
containing 5% CO2. When A549 cells were grown to ap-
proximately 60-70% confluence, they were washed five
times with SFM to remove albumin and other elements
contained in FBS. Cells were then either infected with
10 CFU/cell of M. pneumoniae in SFM or left untreated
for further conditioned media (CM) collection. Cell viabil-
ity in SFM was assessed by MTT test and trypan blue ex-
clusion assay, and the cell death was assessed by apoptosis
assay using the Annexin V-FITC/PI Kit (Multiscience,
Hangzhou, China).
Sample preparation
The CM was harvested 24 h after infection by centrifu-
gation at 9,000 g for 15 min to remove floating cells and
cellular debris, and filtered through a 0.22 μm filter
(Chemicon, Millipore, MA, USA). After the addition of
protease inhibitors (Inhibitor cocktail complete, Roche
Diagnostics, Mannheim, Germany), the media was concen-
trated using the Amicon Ultra-15 (Millipore) centrifugal
filter devices with a 3,000-nomina-weight limit (NMWL).
The supernatants were subsequently precipitated by acet-
one at −20°C overnight, and harvested by centrifugation
at 16,000 g for 20 min. The protein pellets were dried in
air and then resuspended in an appropriate volume of
reducing solution containing 6 M urea, 2 M thiourea
and 25 mM ammonium bicarbonate (Sigma, St Louis,
MO). The protein concentrations were determined by
the Bradford assay (Bio-Rad, Hercules, CA). 100 μg of
each sample was reduced with 10 mM DTT (Sigma) at
37°C for 2.5 h, and then carbamidomethylated with 50 mM
iodoacetamide (IAA) (Sigma) at room temperature in the
dark for 40 min. Subsequently, digestion was performed by
sequencing grade trypsin (Promega, Madison, WI) using a
1:50 enzyme:protein ratio at 37°C for 20 h. After digestion,
samples were lyophilized under vacuum and kept at −80°C
until use. Three independent experiments were performed
and samples were prepared individually for further study.
Total cell lysates from the A549 cells were prepared as
previously described [3]. Briefly, cells were washed and
detached on ice in phosphate-buffered saline (PBS), and
lysed in cell lysis buffer containing 7 M urea, 2 M thiourea,
4% CHAPS, 65 mM DTT, and 0.2% biolyte (Bio-Rad). The
lysates were frozen and thawed with liquid nitrogen three
times, and then centrifuged for 1 h at 10,000 g to remove
cellular debris. The supernatant was then collected for fur-
ther Western blot analysis.LC-MS/MS
All of the mass analyses were performed using a nano-LC-
MS/MS system, which consisted of a nano-HPLC system
(the Ettan MDLC system; GE Healthcare, Piscataway, NJ)
and a linear trap quadruple (LTQ) mass spectrometer
(LTQ VELOS; Thermo Finnigan, San Jose, CA) equipped
with a nano-ESI source. A RP trap column (Zorbax 300SB-
C18 peptide traps, Agilent Technologies, Wilmington, DE)
was used for desalting of samples, and a C18 reverse-phase
column (150 μm i.d., 150 mm length, Column Technology
Inc., Fremont, CA) was used for separation. Mobile phase
A consisted of HPLC-grade water containing 0.1% formic
acid (FA), and phase B consisted of 84% HPLC-grade
acetonitrile (ACN) containing 0.1% FA. The analytical sep-
aration was run at a flow rate of 2 μl/min by using a linear
gradient of phase B as follows: 4%-50% for 105 min, 50%-
100% for 9 min and 100% for 6 min. The eluent was then
introduced into the LTQ mass spectrometer with the ESI
spray voltage set at 3.2 kV. For MS survey scans, each scan
cycle consisted of one full MS scan, and five MS/MS events
were analyzed. The LC-MS/MS analyses were repeated
three times for each independent biological sample. Then
the LC-MS/MS results were pooled for each biological rep-
licates to reduce technical variation.
Data analysis and label-free quantitation
We created the peak lists from original RAW files with
Bioworks Browser software (version 3.1, Thermo Electron,
San Jose, CA) with the minimum peak intensity of 1000.
Peptide identification was performed from each experi-
ment with TurboSEQUEST program in the Bioworks
Browser software suite by automatically searching against
the nonredundant International Protein Index (IPI) hu-
man protein database (version 3.60) with decoy sequences
(reverse of target database). The search parameters were
set as: (a) trypsin digestion; (b) up to two missed cuts
allowed; (c) cysteine carbamidomethylation as a fixed
modification and methionine oxidation as a variable modi-
fication; and (d) mass tolerances set at 3.0 Da for the
precursor ions and 1.0 Da for fragment ones. For pro-
tein identification, Delta Cn (≥0.1) and cross-correlation
scores (Xcorr, one charge ≥1.9, two charges ≥2.2, three
charges ≥3.75) were required. Only proteins identified
by at least two unique peptides with good-quality tan-
dem MS/MS data were reported. False discovery rate
(FDR) was calculated by searching against a sequence-
reversed decoy IPI human version 3.60 databases using
the same search parameters and was estimated to be
2.0%. Multiple or ambiguous IDs were not allowed, and
the decoy database hits were removed from the results.
We also removed frequently observed contaminants such
as porcine trypsin and human keratins.
To estimate the fold-changes in the levels of identi-
fied proteins between the experimental groups, we used
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version 2.0, GE Healthcare) for comparison and label-free
relative quantitation of LC-MS/MS data [52,53]. The rela-
tive quantitation analysis consisted of two main proce-
dures. Firstly, the PepDetect module of the software was
employed for automated peptide detection, charge state
assignments based on resolved isotopic peaks and consist-
ent spacing between consecutive charge states, and quan-
titation based on MS signal intensities. The final step was
to automatically match peptide within a mass and time
tolerance window (0.5 Da and 2 min, respectively) across
different signal intensity maps with PepMatch module,
resulted in a quantitative comparison. The entire pep-
tide intensity distributions detected in each sample were
applied for normalization and peptides were identified
by importing TurboSEQUEST search results to the Pep-
Match module.
Bioinformatics analysis
Classical secretory proteins with a signal peptide were
predicted by SignalP4.1 and were selected on the basis
of their D-value above 0.45 [54]. Non-classical secretory
proteins without a signal peptide were predicted by Secre-
tomP 2.0 and were selected by their neural network (NN)
score≥0.5 [55]. Simultaneously, all the identified proteins
were searched against ExoCarta data to determine whether
they were present in exosome fractions [22]. The identified
proteins were classified on the basis of their cellular com-
partment by Gene Ontology (GO) annotation [56]. The
enrichment analysis of functional annotation clustering
based on cellular compartment were performed by Data-
base for Annotation, Visualization and Integrated Discovery
(DAVID) Bioinformatics Resources 6.7, with an enrichment
score≥1.3 and an EASE score < 0.05 [57]. DAVID 6.7 was
also used to recognize functional Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway categories [58].
Biological Networks Gene Ontology (BiNGO) (version
2.44), a Cytoscape plugin (version 2.8.2), was also used
to determine over-representation of GO categories [59].
Over-representation statistics were calculated by means
of hypergeometric analysis followed by Benjamini &
Hochberg FDR correction. Finally, Search Tool for the
Retrieval of Interacting Genes (STRING) 9.05 was per-
formed to construct a network model showing protein in-
teractions based on known and predicted protein-protein
interactions [26].
Western blotting
Western blots were performed as described previously,
with some modifications [3]. Briefly, equal amounts of pro-
tein from total cell lysates or concentrated cell culture su-
pernatants were denatured, separated on 12% SDS-PAGE
gels and transferred to PVDF membranes (Millipore). For
detection, the membranes were incubated with variousprimary antibodies overnight at 4°C, followed by addition
of fluorescence-labeled secondary antibody (Li-COR Bio-
sciences, diluted 1:5000) for 1 h at room temperature. The
membranes were then scanned using the Odyssey infrared
imaging system (LI-COR Bioscience). The primary anti-
bodies utilized included rabbit polyclonal anti-ADAM9
antibody (Cell Signaling Technolgoy, Beverly, MA, USA,
diluted 1:1000), rabbit polyclonal anti-Gal1 antibody (Pro-
teintech, Chicago, IL, diluted 1:1500), rabbit polyclonal
anti-MIF antibody (Proteintech, diluted 1:2000), rabbit
polyclonal anti-IL33 antibody (Proteintech, diluted 1:600),
rabbit polyclonal anti-SERPINE1 antibody (Proteintech, di-
luted 1:800), rabbit polyclonal anti-IGFBP4 antibody (Milli-
pore, diluted 1:1000), mouse monoclonal anti-β-actin
antibody (Upstate, Lake Placid, NY, diluted 1:3000).
Quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen, Carlbad, CA) according to the manufacturer’s in-
structions. Subsequently, 500 ng of the RNA was reverse
transcribed into cDNA using PrimeScript RT reagent Kit
(Takara, Otsu, Japan), and then quantitative real-time
PCR was carried out in an ABI PRISM 7900HT Real-
Time PCR system using the SYBR Premix Ex Taq Kit
(Takara) according to the manufacturer’s instructions.
The thermal cycling conditions were: 30 sec at 95°C for
initial denaturation, followed by 40 cycles of 5 sec at 95°C,
30 sec at 60°C for amplification, and 15 sec at 95°C, 1 min
at 60°C and 15 sec at 95°C for melting curve analysis. Target
gene primers are presented in Additional file 8: Table S3, in
the supplemental material. An untreated cell sample was
used as the calibrator and the fold-change for this sample
was set as 1. Target gene Ct values were normalized to
β-actin, and the results were analyzed by means of the
2-△△Ct method [60].
Measurement of IL-33 cytokine by enzyme linked
immunosorbent assay
Peripheral blood and bronchoalveolar lavage fluid (BALF)
samples of 30 pediatric patients with MPP (aged from
2.08-8.75 years old) were collected from Children’s Hos-
pital, Zhejiang University School of Medicine from January
2012 to December 2012. Samples from age-matched chil-
dren (aged from 2.50-8.50 years old) with foreign body in
bronchus were used as controls. All samples were collected
with informed consent from their guardians. This study
was approved by the Ethics Committee of the Children’s
Hospital, Zhejiang University School of Medicine. The pro-
cedure of fiberoptic bronchoscopy (FOB) and BALF collec-
tion were performed as described previously [61]. The
samples were centrifuged at 2000 g for 10 min, and the su-
pernatants were stored at −80°C until analysis. The levels
of IL-33 in serum and BALF were determined using the
IL-33 enzyme-linked immunosorbent assay (ELISA) kits
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Statistical analysis
Each experiment was repeated at least three times in-
dependently. Data were expressed as mean ± SD and
evaluated with Student’s t-test or Mann–Whitney U test.
p < 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. Assessment of A549 cell growth in serum-
free medium. (A) Relative viability of cells was determined by the MTT assay.
Mean absorption was normalized to control, with controls (untreated + SM
group) being 100%. (B) Cell growth rate was investigated by cell count. (C) Cell
viability was measured by Trypan blue exclusion assay. (D) Micrographs (200×)
of cell morphology. The values represent averages of three independent
experiments with six replicate detections (mean ± SD). *, M. pneumoniae-
treated + SFM group vs M. pneumoniae-treated + SM group, p<0.05; #,
Untreated + SFM group vs Untreated + SM group, p<0.05. SM: medium
containing 10% FBS; SFM: serum-free medium.
Additional file 2: Figure S2. Cell death analysis of A549 cells growing
in SFM for 24 h. Cell apoptosis/necrosis was analyzed by dual-parameter
flow cytometry stained with Annexin V-FITC and PI. (A) Representative
dot plot images from three independent experiments. (B) Quantitative
analysis results from (A). Data are presented as mean ± SD.
Additional file 3: Figure S3. Venn diagrams of identified proteins. The
overlaps of identified proteins in each biological replicate were shown in
(A) for untreated and (B) for M. pneumoniae-treated A549 cells. (C) shows
the overlaps of the non-redundant proteins identified between control
and infected cells.
Additional file 4: Datasheet S1. Database search results for all the
secretory proteins identified in this study.
Additional file 5: Table S1. Basic information of identified proteins.
Additional file 6: Table S2. Differentially expressed proteins identified
in the secretome of Mycoplasma pneumoniae-infected A549 and
untreated A549 cells.
Additional file 7: Figure S4. Functional gene ontology (GO) analysis of
the differentially expressed secretory proteins during M. pneumoniae
infection. (A) GO analysis of cellular component distribution for proteins
that are down-regulated by M. pneumoniae treatment. (B) GO analysis of
molecular function distribution for proteins that are up-regulated by M.
pneumoniae treatment. (C) GO analysis of molecular function distribution
for proteins that are down-regulated by M. pneumoniae treatment. (D)
GO analysis of biological process distribution of clusters for proteins that
are up-regulatedby M. pneumoniae treatment. (E) GO analysis of
biological process distribution of clusters for proteins that are
down-regulated by M. pneumoniae treatment. Over-representation of GO
categories was analyzed using the Biological Networks Gene Ontology
plugin (BINGO, version 2.44). Over-representation statistics were calculated
by using the hypergeometric analysis and Benjamini & Hochberg False
Discovery Rate (FDR) correction. Only categories that are significantly
enriched after correction are represented. The color scales indicate the
p value range for over-representation. The node size is proportional to the
number of proteins annotated with the GO term.
Additional file 8: Table S3. Primers used for PCR amplification.
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